SIMILAR PATTERNS OF AMINO ACIDS FOR 1XKK_A_FMMA91_2

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1cm8	PHOSPHORYLATED MAP KINASE P38-GAMMA (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 41 LYS A 56 LEU A 89 LEU A 107 MET A 112	ANP A 400 (-4.1A) ANP A 400 (-2.9A) None None None	0.68A	1xkkA-1cm8A: 21.2	1xkkA-1cm8A: 27.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	LEU A 267 VAL A 275 LYS A 290 LEU A 320 MET A 337	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) None None	0.64A	1xkkA-1opkA: 29.2	1xkkA-1opkA: 24.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ua2	CELL DIVISION PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 18 VAL A 26 LEU A 77 LEU A 89 MET A 94	ATP A 381 (-4.4A) ATP A 381 (-4.0A) None None None	0.50A	1xkkA-1ua2A: 22.9	1xkkA-1ua2A: 22.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ua2	CELL DIVISION PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 18 VAL A 26 LYS A 41 LEU A 77 LEU A 89	ATP A 381 (-4.4A) ATP A 381 (-4.0A) ATP A 381 (-2.9A) None None	0.76A	1xkkA-1ua2A: 22.9	1xkkA-1ua2A: 22.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zws	DAP-KINASE RELATED PROTEIN 1 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 19 VAL A 27 LEU A 79 LEU A 91 LEU A 95	None	0.69A	1xkkA-1zwsA: 11.9	1xkkA-1zwsA: 25.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2a2a	DEATH-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 LYS A 42 LEU A 79 LEU A 91 LEU A 95	None	0.73A	1xkkA-2a2aA: 22.9	1xkkA-2a2aA: 24.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2b1p	MITOGEN-ACTIVATED PROTEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 78 LYS A 93 LEU A 126 LEU A 144 LEU A 148 MET A 149	AIZ A 501 ( 4.7A) AIZ A 501 (-3.8A) None AIZ A 501 (-4.2A) AIZ A 501 ( 4.7A) None	0.49A	1xkkA-2b1pA: 18.4	1xkkA-2b1pA: 23.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2bdw	HYPOTHETICAL PROTEIN K11E8.1D (Caenorhabditis elegans)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 LYS A 42 LEU A 75 LEU A 87 LEU A 91	None	0.83A	1xkkA-2bdwA: 20.9	1xkkA-2bdwA: 23.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2f9g	MITOGEN-ACTIVATED PROTEIN KINASE FUS3 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	5	LEU A 19 VAL A 27 LYS A 42 LEU A 95 MET A 96	ADP A 500 (-4.3A) ADP A 500 (-4.3A) ADP A 500 (-2.9A) ADP A 500 ( 4.9A) None	0.70A	1xkkA-2f9gA: 21.2	1xkkA-2f9gA: 24.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 LYS A 295 LEU A 325 MET A 341 LEU A 407	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.7A) None None None	0.58A	1xkkA-2h8hA: 33.3	1xkkA-2h8hA: 23.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	LEU A 273 VAL A 281 LYS A 295 LEU A 325 MET A 341	QUE A 1 (-3.9A) QUE A 1 ( 4.8A) None None None	0.62A	1xkkA-2hckA: 31.3	1xkkA-2hckA: 27.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 248 VAL A 256 LYS A 271 LEU A 301 MET A 318	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.6A) None None	0.76A	1xkkA-2hz0A: 29.8	1xkkA-2hz0A: 34.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jam	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1G (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 29 VAL A 37 LEU A 84 LEU A 96 LEU A 100	J60 A1305 (-3.9A) J60 A1305 (-4.8A) None None J60 A1305 (-4.4A)	0.42A	1xkkA-2jamA: 14.8	1xkkA-2jamA: 25.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jam	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1G (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 37 LYS A 52 LEU A 84 LEU A 96 LEU A 100	J60 A1305 (-4.8A) EDO A1304 ( 2.9A) None None J60 A1305 (-4.4A)	0.59A	1xkkA-2jamA: 14.8	1xkkA-2jamA: 25.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jc6	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1D (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 29 VAL A 37 LYS A 52 LEU A 84 LEU A 96 LEU A 100	QPP A1314 (-3.7A) QPP A1314 ( 4.6A) None None None QPP A1314 (-4.5A)	0.61A	1xkkA-2jc6A: 20.4	1xkkA-2jc6A: 26.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 344 VAL A 352 LYS A 369 LEU A 401 LEU A 412 LEU A 482	ANP A 615 (-4.4A) ANP A 615 (-4.5A) ANP A 615 (-3.1A) None None None	0.91A	1xkkA-2ozoA: 31.6	1xkkA-2ozoA: 21.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	6	LEU A 25 VAL A 33 LEU A 89 LEU A 101 LEU A 105 MET A 106	ATP A 381 ( 4.3A) ATP A 381 (-4.1A) None None None None	0.56A	1xkkA-2phkA: 21.9	1xkkA-2phkA: 26.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 724 VAL A 732 LYS A 751 LEU A 783 LEU A 794 LEU A 798 MET A 799 LEU A 864	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.9A) GW7 A 1 (-3.9A) GW7 A 1 (-4.1A) GW7 A 1 (-4.5A) None GW7 A 1 ( 4.7A)	0.33A	1xkkA-2r4bA: 39.6	1xkkA-2r4bA: 76.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2w4k	DEATH-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 LYS A 42 LEU A 79 LEU A 91 LEU A 95	ADP A1303 ( 3.9A) ADP A1303 (-4.0A) ADP A1303 (-2.7A) None None None	0.70A	1xkkA-2w4kA: 17.1	1xkkA-2w4kA: 24.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2w4o	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE IV (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 52 VAL A 60 LEU A 104 LEU A 116 LEU A 120	DKI A1338 (-3.8A) DKI A1338 (-4.2A) None None DKI A1338 (-4.2A)	0.44A	1xkkA-2w4oA: 22.1	1xkkA-2w4oA: 27.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2w4o	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE IV (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 60 LYS A 75 LEU A 104 LEU A 116 LEU A 120	DKI A1338 (-4.2A) None None None DKI A1338 (-4.2A)	0.63A	1xkkA-2w4oA: 22.1	1xkkA-2w4oA: 27.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wbi	ACYL-COA DEHYDROGENASE FAMILY MEMBER 11 (Homo sapiens)	PF00441 (Acyl-CoA_dh_1) PF02770 (Acyl-CoA_dh_M) PF02771 (Acyl-CoA_dh_N)	6	LEU A 127 VAL A 126 CYH A 153 LEU A 201 LEU A 219 LEU A 276	None	1.23A	1xkkA-2wbiA: undetectable	1xkkA-2wbiA: 21.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2x4f	MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 112 VAL A 120 LYS A 135 LEU A 166 LEU A 178	16X A1374 (-4.1A) 16X A1374 (-4.8A) 16X A1374 ( 4.3A) None None	0.47A	1xkkA-2x4fA: 22.8	1xkkA-2x4fA: 25.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 226 VAL A 234 LYS A 249 LEU A 303 MET A 304	XK9 A1511 (-3.8A) XK9 A1511 (-4.8A) XK9 A1511 (-4.2A) XK9 A1511 (-4.1A) None	0.73A	1xkkA-2xk9A: 20.9	1xkkA-2xk9A: 25.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 38 LEU A 93 LEU A 105 LEU A 109 MET A 110	None None None B49 A1294 ( 4.7A) None	0.45A	1xkkA-2y7jA: 22.4	1xkkA-2y7jA: 25.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 38 LYS A 53 LEU A 93 LEU A 105 MET A 110	None	0.65A	1xkkA-2y7jA: 22.4	1xkkA-2y7jA: 25.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2yab	DEATH-ASSOCIATED PROTEIN KINASE 2 (Mus musculus)	PF00069 (Pkinase)	5	LEU A 19 VAL A 27 LEU A 79 LEU A 91 LEU A 95	AMP A1302 (-3.7A) AMP A1302 (-4.2A) None None AMP A1302 ( 4.9A)	0.55A	1xkkA-2yabA: 23.1	1xkkA-2yabA: 25.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2yab	DEATH-ASSOCIATED PROTEIN KINASE 2 (Mus musculus)	PF00069 (Pkinase)	5	VAL A 27 LYS A 42 LEU A 79 LEU A 91 LEU A 95	AMP A1302 (-4.2A) AMP A1302 (-2.8A) None None AMP A1302 ( 4.9A)	0.75A	1xkkA-2yabA: 23.1	1xkkA-2yabA: 25.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 68 VAL A 76 LYS A 94 LEU A 127 LEU A 139	STU A 1 (-3.8A) None STU A 1 (-2.8A) None None	0.54A	1xkkA-2z7rA: 22.5	1xkkA-2z7rA: 26.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A1002 VAL A1010 LEU A1062 LEU A1078 MET A1079	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) None S91 A 1 (-4.7A) None	0.57A	1xkkA-2z8cA: 22.4	1xkkA-2z8cA: 31.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A1002 VAL A1010 LYS A1030 LEU A1062 LEU A1078	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 ( 4.2A) None S91 A 1 (-4.7A)	0.61A	1xkkA-2z8cA: 22.4	1xkkA-2z8cA: 31.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3a14	1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE (Thermotoga maritima)	PF02670 (DXP_reductoisom) PF08436 (DXP_redisom_C) PF13288 (DXPR_C)	5	LEU A 9 VAL A 91 LEU A 131 LEU A 138 LEU A 120	None	0.83A	1xkkA-3a14A: undetectable	1xkkA-3a14A: 22.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3bqr	DEATH-ASSOCIATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 19 VAL A 27 LEU A 79 LEU A 91 LEU A 95	4RB A 401 ( 3.9A) 4RB A 401 ( 4.4A) PGO A 501 ( 4.6A) None 4RB A 401 (-4.4A)	0.47A	1xkkA-3bqrA: 20.9	1xkkA-3bqrA: 24.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3coi	MITOGEN-ACTIVATED PROTEIN KINASE 13 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 39 LYS A 54 LEU A 87 LEU A 105 MET A 110	None	0.75A	1xkkA-3coiA: 19.1	1xkkA-3coiA: 26.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dxn	CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3 (Toxoplasma gondii)	PF00069 (Pkinase)	5	LEU A 29 VAL A 37 LEU A 86 LEU A 98 LEU A 170	None	0.72A	1xkkA-3dxnA: 25.2	1xkkA-3dxnA: 27.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3e7o	MITOGEN-ACTIVATED PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 40 LYS A 55 LEU A 88 LEU A 106 LEU A 110 MET A 111	35F A 1 ( 4.8A) 35F A 1 ( 4.6A) None None 35F A 1 (-4.5A) None	0.66A	1xkkA-3e7oA: 19.6	1xkkA-3e7oA: 25.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3f2a	PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 44 VAL A 52 LYS A 67 LEU A 106 LEU A 118	985 A 1 (-4.1A) 985 A 1 (-4.5A) 985 A 1 ( 2.8A) None None	0.65A	1xkkA-3f2aA: 16.9	1xkkA-3f2aA: 23.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3f3z	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase)	5	VAL A 42 LYS A 57 LEU A 88 LEU A 100 LEU A 104	DRK A 1 ( 4.9A) DRK A 1 (-4.1A) None None DRK A 1 (-4.4A)	0.54A	1xkkA-3f3zA: 22.2	1xkkA-3f3zA: 24.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gbz	KINASE, CMGC CDK (Giardia intestinalis)	PF00069 (Pkinase)	6	LEU A 21 VAL A 29 LYS A 44 LEU A 77 LEU A 89 LEU A 162	None	1.10A	1xkkA-3gbzA: 18.1	1xkkA-3gbzA: 27.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gp0	MITOGEN-ACTIVATED PROTEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 38 LEU A 86 LEU A 104 LEU A 108 MET A 109	NIL A 1 ( 4.7A) None NIL A 1 ( 4.3A) NIL A 1 ( 4.4A) None	0.63A	1xkkA-3gp0A: 20.5	1xkkA-3gp0A: 25.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gp0	MITOGEN-ACTIVATED PROTEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 38 LYS A 53 LEU A 86 LEU A 104 LEU A 108	NIL A 1 ( 4.7A) None None NIL A 1 ( 4.3A) NIL A 1 ( 4.4A)	0.67A	1xkkA-3gp0A: 20.5	1xkkA-3gp0A: 25.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hko	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase)	5	VAL A 24 LYS A 39 LEU A 75 LEU A 87 LEU A 91	ANP A 329 (-4.4A) ANP A 329 (-2.7A) None None ANP A 329 ( 4.7A)	0.79A	1xkkA-3hkoA: 20.1	1xkkA-3hkoA: 25.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3igo	CALMODULIN-DOMAIN PROTEIN KINASE 1 (Cryptosporidium parvum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	LEU A 82 VAL A 90 LYS A 105 LEU A 154 LEU A 222	ANP A 610 ( 4.5A) ANP A 610 (-3.9A) ANP A 610 (-2.8A) GOL A 1 (-4.6A) None	0.80A	1xkkA-3igoA: 21.9	1xkkA-3igoA: 24.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 696 VAL A 704 LYS A 723 LEU A 755 LEU A 766	ANP A 1 (-4.4A) ANP A 1 (-3.9A) ANP A 1 (-3.4A) None None	0.40A	1xkkA-3kexA: 36.0	1xkkA-3kexA: 51.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kl8	CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE II (Caenorhabditis elegans)	PF00069 (Pkinase)	5	VAL A 27 LYS A 42 LEU A 75 LEU A 87 LEU A 91	None	0.56A	1xkkA-3kl8A: 21.4	1xkkA-3kl8A: 23.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lij	CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	LEU A 68 VAL A 76 LYS A 91 LEU A 124 LEU A 136	ANP A 522 (-4.6A) ANP A 522 (-4.1A) ANP A 522 (-3.5A) None None	0.53A	1xkkA-3lijA: 23.2	1xkkA-3lijA: 23.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 39 VAL A 47 LYS A 62 LEU A 96 LEU A 108	QUE A 1 ( 3.8A) QUE A 1 ( 4.6A) QUE A 1 (-4.1A) None None	0.78A	1xkkA-3lm5A: 23.3	1xkkA-3lm5A: 27.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 694 VAL A 702 CYH A 751 LEU A 753 LEU A 768 MET A 769	ITI A 1 (-3.9A) ITI A 1 (-4.8A) ITI A 1 (-3.7A) ITI A 1 (-3.8A) ITI A 1 (-4.8A) ITI A 1 (-4.8A)	1.14A	1xkkA-3lzbA: 38.3	1xkkA-3lzbA: 87.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 694 VAL A 702 LEU A 753 LEU A 764 LEU A 768 MET A 769	ITI A 1 (-3.9A) ITI A 1 (-4.8A) ITI A 1 (-3.8A) ITI A 1 ( 4.2A) ITI A 1 (-4.8A) ITI A 1 (-4.8A)	0.93A	1xkkA-3lzbA: 38.3	1xkkA-3lzbA: 87.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 694 VAL A 702 LYS A 721 LEU A 753 LEU A 764 LEU A 768	ITI A 1 (-3.9A) ITI A 1 (-4.8A) ITI A 1 (-2.6A) ITI A 1 (-3.8A) ITI A 1 ( 4.2A) ITI A 1 (-4.8A)	0.81A	1xkkA-3lzbA: 38.3	1xkkA-3lzbA: 87.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 702 CYH A 751 LEU A 753 LEU A 768 MET A 769 LEU A 834	ITI A 1 (-4.8A) ITI A 1 (-3.7A) ITI A 1 (-3.8A) ITI A 1 (-4.8A) ITI A 1 (-4.8A) None	1.19A	1xkkA-3lzbA: 38.3	1xkkA-3lzbA: 87.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 702 LEU A 753 LEU A 764 LEU A 768 MET A 769 LEU A 834	ITI A 1 (-4.8A) ITI A 1 (-3.8A) ITI A 1 ( 4.2A) ITI A 1 (-4.8A) ITI A 1 (-4.8A) None	1.01A	1xkkA-3lzbA: 38.3	1xkkA-3lzbA: 87.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 702 LYS A 721 LEU A 753 LEU A 764 LEU A 768 LEU A 834	ITI A 1 (-4.8A) ITI A 1 (-2.6A) ITI A 1 (-3.8A) ITI A 1 ( 4.2A) ITI A 1 (-4.8A) None	0.95A	1xkkA-3lzbA: 38.3	1xkkA-3lzbA: 87.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3niz	RHODANESE FAMILY PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	5	VAL A 37 LYS A 51 LEU A 84 LEU A 96 MET A 101	ADP A 314 (-4.0A) ADP A 314 (-2.8A) None None None	0.78A	1xkkA-3nizA: 22.6	1xkkA-3nizA: 29.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 192 VAL A 200 LEU A 238 LEU A 261 LEU A 265 MET A 266	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) None None AMP A 577 ( 4.9A) None	1.17A	1xkkA-3nyoA: 21.4	1xkkA-3nyoA: 19.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 192 VAL A 200 LEU A 249 LEU A 261 LEU A 265 MET A 266	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) None None AMP A 577 ( 4.9A) None	0.70A	1xkkA-3nyoA: 21.4	1xkkA-3nyoA: 19.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	VAL A 200 LYS A 215 LEU A 249 LEU A 261 LEU A 265 MET A 266	AMP A 577 (-4.3A) AMP A 577 (-2.8A) None None AMP A 577 ( 4.9A) None	0.77A	1xkkA-3nyoA: 21.4	1xkkA-3nyoA: 19.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3oht	P38A (Salmo salar)	PF00069 (Pkinase)	5	LYS A 54 LEU A 87 LEU A 105 LEU A 109 MET A 110	1N1 A1000 (-4.5A) None 1N1 A1000 (-4.2A) 1N1 A1000 (-4.7A) None	0.77A	1xkkA-3ohtA: 6.8	1xkkA-3ohtA: 27.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3oht	P38A (Salmo salar)	PF00069 (Pkinase)	5	VAL A 39 LEU A 87 LEU A 105 LEU A 109 MET A 110	1N1 A1000 (-4.6A) None 1N1 A1000 (-4.2A) 1N1 A1000 (-4.7A) None	0.77A	1xkkA-3ohtA: 6.8	1xkkA-3ohtA: 27.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 726 VAL A 734 LEU A 785 LEU A 796 LEU A 800 MET A 801	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.3A) 03Q A 1 (-4.6A) None	0.31A	1xkkA-3pp0A: 29.5	1xkkA-3pp0A: 73.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 734 LYS A 753 LEU A 785 LEU A 796 LEU A 800 MET A 801	03Q A 1 (-4.5A) 03Q A 1 (-4.7A) 03Q A 1 (-3.1A) 03Q A 1 (-4.3A) 03Q A 1 (-4.6A) None	0.55A	1xkkA-3pp0A: 29.5	1xkkA-3pp0A: 73.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	LEU A 63 VAL A 71 LYS A 86 LEU A 130 LEU A 142	ANP A1634 ( 4.3A) ANP A1634 (-4.1A) ANP A1634 (-3.1A) None None	0.68A	1xkkA-3q5iA: 21.2	1xkkA-3q5iA: 23.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3soa	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II SUBUNIT ALPHA WITH A BETA 7 LINKER (Homo sapiens)	PF00069 (Pkinase) PF08332 (CaMKII_AD)	5	LEU A 19 VAL A 27 LEU A 75 LEU A 87 LEU A 91	DB8 A 445 (-3.5A) DB8 A 445 (-4.5A) None None None	0.73A	1xkkA-3soaA: 19.3	1xkkA-3soaA: 23.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxf	CALMODULIN-DOMAIN PROTEIN KINASE 1 (Toxoplasma gondii)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 57 VAL A 65 LYS A 80 LEU A 114 LEU A 126 LEU A 198	BK5 A 701 ( 4.2A) BK5 A 701 (-4.2A) BK5 A 701 (-3.5A) BK5 A 701 ( 4.5A) BK5 A 701 (-3.3A) BK5 A 701 ( 4.9A)	0.52A	1xkkA-3sxfA: 24.2	1xkkA-3sxfA: 22.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	5	LEU A 295 LYS A 317 LEU A 349 LEU A 361 MET A 366	None	0.69A	1xkkA-3ulzA: 22.3	1xkkA-3ulzA: 26.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3w18	AURORA KINASE A (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 139 VAL A 147 LYS A 162 LEU A 196 LEU A 208	N13 A 501 (-3.7A) N13 A 501 ( 4.7A) N13 A 501 (-2.9A) N13 A 501 ( 4.8A) N13 A 501 (-4.9A)	0.52A	1xkkA-3w18A: 21.6	1xkkA-3w18A: 23.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 83 VAL A 91 LYS A 106 LEU A 140 LEU A 152	VX6 A 500 (-3.8A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.3A) None None	0.53A	1xkkA-4af3A: 19.0	1xkkA-4af3A: 24.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 616 VAL A 624 LYS A 655 LEU A 687 MET A 704	None DI1 A1000 (-4.8A) DI1 A1000 (-3.9A) None None	0.81A	1xkkA-4ckrA: 27.4	1xkkA-4ckrA: 31.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eut	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 15 VAL A 23 LYS A 38 LEU A 70 LEU A 84	BX7 A 401 (-3.7A) BX7 A 401 (-4.4A) BX7 A 401 ( 4.0A) None None	0.73A	1xkkA-4eutA: 11.1	1xkkA-4eutA: 23.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fg8	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 26 VAL A 34 LYS A 49 LEU A 81 LEU A 93 LEU A 97	ATP A 401 (-3.8A) ATP A 401 (-4.1A) ATP A 401 (-3.0A) None None ATP A 401 ( 4.8A)	0.62A	1xkkA-4fg8A: 22.8	1xkkA-4fg8A: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	5	LEU A 377 VAL A 385 LYS A 402 LEU A 446 LEU A 515	ANP A 701 ( 4.6A) ANP A 701 (-4.1A) ANP A 701 (-2.7A) None None	0.44A	1xkkA-4fl3A: 21.9	1xkkA-4fl3A: 22.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	LEU A 132 VAL A 140 LYS A 158 LEU A 192 LEU A 207 LEU A 273	None	0.70A	1xkkA-4hzsA: 21.6	1xkkA-4hzsA: 36.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4i93	PROBABLE SERINE/THREONINE-PRO TEIN KINASE AT5G41260 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	5	VAL A 73 LYS A 87 LEU A 118 LEU A 130 MET A 135	None	0.72A	1xkkA-4i93A: 23.9	1xkkA-4i93A: 25.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	LEU A 132 VAL A 140 LYS A 158 LEU A 192 LEU A 207	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.7A) 1G0 A 401 ( 3.8A) 1G0 A 401 ( 4.9A)	0.72A	1xkkA-4id7A: 30.5	1xkkA-4id7A: 34.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jxf	SERINE/THREONINE-PRO TEIN KINASE PLK4 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 18 VAL A 26 LYS A 41 LEU A 75 LEU A 87	631 A 301 (-3.4A) 631 A 301 (-4.6A) 631 A 301 (-2.7A) None None	0.67A	1xkkA-4jxfA: 18.4	1xkkA-4jxfA: 25.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 LYS A 295 LEU A 325 MET A 341 LEU A 407	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 ( 4.7A) None None None	0.76A	1xkkA-4k11A: 33.1	1xkkA-4k11A: 26.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4l68	LEUCINE-RICH REPEAT PROTEIN KINASE-LIKE PROTEIN (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	5	LYS A 335 LEU A 365 LEU A 377 MET A 382 LEU A 450	None	0.54A	1xkkA-4l68A: 22.3	1xkkA-4l68A: 23.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL A 36 LYS A 51 LEU A 76 LEU A 93 MET A 98 LEU A 164	ANP A 401 (-4.5A) ANP A 401 (-2.9A) None None None None	0.67A	1xkkA-4m69A: 27.3	1xkkA-4m69A: 25.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mvf	CALCIUM-DEPENDENT PROTEIN KINASE 2 (Plasmodium falciparum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	LEU A 78 VAL A 86 LEU A 132 LEU A 144 LEU A 148	STU A 601 ( 4.0A) STU A 601 (-4.8A) None None STU A 601 (-4.3A)	0.50A	1xkkA-4mvfA: 19.0	1xkkA-4mvfA: 24.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 46 VAL A 54 LYS A 69 LEU A 121 LEU A 125	SIN A 401 ( 3.9A) None None None SIN A 401 ( 4.8A)	0.59A	1xkkA-4o38A: 18.7	1xkkA-4o38A: 21.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rgj	CALCIUM-DEPENDENT PROTEIN KINASE 4 (Plasmodium falciparum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 76 VAL A 84 LYS A 99 LEU A 133 LEU A 145 LEU A 218	None	0.65A	1xkkA-4rgjA: 23.4	1xkkA-4rgjA: 22.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tyh	MITOGEN-ACTIVATED PROTEIN KINASE 14 (Mus musculus)	PF00069 (Pkinase)	6	VAL B 38 LYS B 53 LEU B 86 LEU B 104 LEU B 108 MET B 109	None 39G B 401 (-4.2A) None 39G B 401 ( 4.7A) 39G B 401 ( 4.9A) 39G B 401 (-4.8A)	0.68A	1xkkA-4tyhB: 20.6	1xkkA-4tyhB: 25.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 193 VAL A 201 LYS A 216 LEU A 250 LEU A 262 MET A 267	ANW A 601 ( 4.0A) None None None None None	0.65A	1xkkA-4wboA: 21.7	1xkkA-4wboA: 21.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	5	LEU A 193 VAL A 201 LEU A 250 LEU A 262 MET A 267	AN2 A 601 ( 4.2A) AN2 A 601 (-4.0A) None None None	0.82A	1xkkA-4yhjA: 20.2	1xkkA-4yhjA: 22.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	5	VAL A 201 LYS A 216 LEU A 250 LEU A 262 MET A 267	AN2 A 601 (-4.0A) AN2 A 601 ( 3.9A) None None None	0.81A	1xkkA-4yhjA: 20.2	1xkkA-4yhjA: 22.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ynz	SERINE/THREONINE-PRO TEIN KINASE BRSK2 (Mus musculus)	PF00069 (Pkinase)	5	LEU A 26 VAL A 34 LYS A 49 LEU A 82 LEU A 94	None	0.42A	1xkkA-4ynzA: 21.7	1xkkA-4ynzA: 24.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ysj	CALMODULIN-LIKE DOMAIN PROTEIN KINASE (Eimeria tenella)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	LEU A 34 VAL A 42 LYS A 57 LEU A 91 LEU A 103	ADP A 506 ( 3.8A) ADP A 506 (-4.3A) ADP A 506 (-2.4A) None None	0.64A	1xkkA-4ysjA: 23.5	1xkkA-4ysjA: 22.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5awm	STRESS-ACTIVATED PROTEIN KINASE JNK (Drosophila melanogaster)	PF00069 (Pkinase)	6	VAL A 38 LYS A 53 LEU A 86 LEU A 104 LEU A 108 MET A 109	ANP A 401 (-4.5A) ANP A 401 (-2.9A) None None ANP A 401 ( 4.8A) None	0.48A	1xkkA-5awmA: 19.4	1xkkA-5awmA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	5	LEU A 20 VAL A 28 LEU A 76 LEU A 88 LEU A 92	ADP A 301 ( 4.0A) ADP A 301 (-3.7A) None None ADP A 301 ( 4.8A)	0.46A	1xkkA-5hu3A: 16.7	1xkkA-5hu3A: 24.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	5	VAL A 28 LYS A 43 LEU A 76 LEU A 88 LEU A 92	ADP A 301 (-3.7A) ADP A 301 (-2.7A) None None ADP A 301 ( 4.8A)	0.75A	1xkkA-5hu3A: 16.7	1xkkA-5hu3A: 24.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 718 VAL A 726 CYH A 775 LEU A 777 LEU A 788 LEU A 792 MET A 793	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) None None 6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.9A) None	0.60A	1xkkA-5j9zA: 32.5	1xkkA-5j9zA: 99.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 726 LYS A 745 CYH A 775 LEU A 777 LEU A 788 LEU A 792 MET A 793	6HJ A1101 ( 4.7A) 6HJ A1101 (-4.2A) None None 6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.9A) None	0.68A	1xkkA-5j9zA: 32.5	1xkkA-5j9zA: 99.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	5	VAL A 897 LYS A 911 LEU A 942 LEU A 954 MET A 959	ATP A1200 ( 4.5A) ATP A1200 (-3.8A) None None None	0.77A	1xkkA-5lpyA: 23.0	1xkkA-5lpyA: 26.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	5	VAL A 897 LYS A 911 LEU A 942 LEU A 954 MET A 959	ADP A1200 (-4.4A) ADP A1200 ( 4.3A) None None None	0.80A	1xkkA-5lpzA: 22.9	1xkkA-5lpzA: 25.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5o2c	SERINE/THREONINE-PRO TEIN KINASE WNK3 (Homo sapiens)	PF00069 (Pkinase) PF12202 (OSR1_C)	5	LEU A 153 VAL A 161 LEU A 225 LEU A 229 MET A 230	None None None GOL A 604 ( 4.8A) None	0.83A	1xkkA-5o2cA: 25.8	1xkkA-5o2cA: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 116 VAL A 124 LEU A 173 LEU A 185 LEU A 189	H8H A 401 (-3.7A) H8H A 401 (-4.7A) None H8H A 401 (-4.3A) None	0.76A	1xkkA-5vcxA: 22.7	1xkkA-5vcxA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	5	VAL A 142 LYS A 157 LEU A 214 LEU A 228 LEU A 232	H1N A 501 (-4.4A) H1N A 501 (-2.8A) None None H1N A 501 (-4.3A)	0.63A	1xkkA-6ccfA: 22.8	1xkkA-6ccfA: 14.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cth	CONCANAVALIN A-LIKE LECTIN PROTEIN KINASE FAMILY PROTEIN (Theobroma cacao)	no annotation	5	LEU A 275 VAL A 283 LEU A 329 LEU A 341 MET A 346	FE7 A 601 (-3.8A) FE7 A 601 ( 4.3A) None None FE7 A 601 (-4.7A)	0.74A	1xkkA-6cthA: 21.7	1xkkA-6cthA: 11.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cth	CONCANAVALIN A-LIKE LECTIN PROTEIN KINASE FAMILY PROTEIN (Theobroma cacao)	no annotation	5	VAL A 283 LYS A 298 LEU A 329 LEU A 341 MET A 346	FE7 A 601 ( 4.3A) FE7 A 601 (-3.6A) None None FE7 A 601 (-4.7A)	0.74A	1xkkA-6cthA: 21.7	1xkkA-6cthA: 11.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	7	LEU A 197 VAL A 205 LYS A 219 LEU A 250 LEU A 266 MET A 267 LEU A 333	FKY A9001 (-4.1A) FKY A9001 ( 4.6A) None None FKY A9001 (-4.4A) None None	0.83A	1xkkA-6cz4A: 30.2	1xkkA-6cz4A: 16.67

[["1XKK_A_FMMA91_2","1cm8","Homo sapiens","PHOSPHORYLATED MAP KINASE P38-GAMMA","PF00069(Pkinase)",5,"VAL A  41;LYS A  56;LEU A  89;LEU A 107;MET A 112","ANP A 400 (-4.1A);ANP A 400 (-2.9A);None;None;None","0.68A","1xkkA-1cm8A:21.2","1xkkA-1cm8A:27.20"],["1XKK_A_FMMA91_2","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"LEU A 267;VAL A 275;LYS A 290;LEU A 320;MET A 337","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);None;None","0.64A","1xkkA-1opkA:29.2","1xkkA-1opkA:24.91"],["1XKK_A_FMMA91_2","1ua2","Homo sapiens","CELL DIVISION PROTEIN KINASE 7","PF00069(Pkinase)",5,"LEU A  18;VAL A  26;LEU A  77;LEU A  89;MET A  94","ATP A 381 (-4.4A);ATP A 381 (-4.0A);None;None;None","0.50A","1xkkA-1ua2A:22.9","1xkkA-1ua2A:22.37"],["1XKK_A_FMMA91_2","1ua2","Homo sapiens","CELL DIVISION PROTEIN KINASE 7","PF00069(Pkinase)",5,"LEU A  18;VAL A  26;LYS A  41;LEU A  77;LEU A  89","ATP A 381 (-4.4A);ATP A 381 (-4.0A);ATP A 381 (-2.9A);None;None","0.76A","1xkkA-1ua2A:22.9","1xkkA-1ua2A:22.37"],["1XKK_A_FMMA91_2","1zws","Homo sapiens","DAP-KINASE RELATED PROTEIN 1","PF00069(Pkinase)",5,"LEU A  19;VAL A  27;LEU A  79;LEU A  91;LEU A  95","None","0.69A","1xkkA-1zwsA:11.9","1xkkA-1zwsA:25.21"],["1XKK_A_FMMA91_2","2a2a","Homo sapiens","DEATH-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;LYS A  42;LEU A  79;LEU A  91;LEU A  95","None","0.73A","1xkkA-2a2aA:22.9","1xkkA-2a2aA:24.15"],["1XKK_A_FMMA91_2","2b1p","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 10","PF00069(Pkinase)",6,"VAL A  78;LYS A  93;LEU A 126;LEU A 144;LEU A 148;MET A 149","AIZ A 501 ( 4.7A);AIZ A 501 (-3.8A);None;AIZ A 501 (-4.2A);AIZ A 501 ( 4.7A);None","0.49A","1xkkA-2b1pA:18.4","1xkkA-2b1pA:23.47"],["1XKK_A_FMMA91_2","2bdw","Caenorhabditis elegans","HYPOTHETICAL PROTEIN K11E8.1D","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;LYS A  42;LEU A  75;LEU A  87;LEU A  91","None","0.83A","1xkkA-2bdwA:20.9","1xkkA-2bdwA:23.28"],["1XKK_A_FMMA91_2","2f9g","Saccharomyces cerevisiae","MITOGEN-ACTIVATED PROTEIN KINASE FUS3","PF00069(Pkinase)",5,"LEU A  19;VAL A  27;LYS A  42;LEU A  95;MET A  96","ADP A 500 (-4.3A);ADP A 500 (-4.3A);ADP A 500 (-2.9A);ADP A 500 ( 4.9A);None","0.70A","1xkkA-2f9gA:21.2","1xkkA-2f9gA:24.74"],["1XKK_A_FMMA91_2","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;LYS A 295;LEU A 325;MET A 341;LEU A 407","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.7A);None;None;None","0.58A","1xkkA-2h8hA:33.3","1xkkA-2h8hA:23.41"],["1XKK_A_FMMA91_2","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"LEU A 273;VAL A 281;LYS A 295;LEU A 325;MET A 341","QUE A   1 (-3.9A);QUE A   1 ( 4.8A);None;None;None","0.62A","1xkkA-2hckA:31.3","1xkkA-2hckA:27.24"],["1XKK_A_FMMA91_2","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",5,"LEU A 248;VAL A 256;LYS A 271;LEU A 301;MET A 318","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.6A);None;None","0.76A","1xkkA-2hz0A:29.8","1xkkA-2hz0A:34.65"],["1XKK_A_FMMA91_2","2jam","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1G","PF00069(Pkinase)",5,"LEU A  29;VAL A  37;LEU A  84;LEU A  96;LEU A 100","J60 A1305 (-3.9A);J60 A1305 (-4.8A);None;None;J60 A1305 (-4.4A)","0.42A","1xkkA-2jamA:14.8","1xkkA-2jamA:25.96"],["1XKK_A_FMMA91_2","2jam","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1G","PF00069(Pkinase)",5,"VAL A  37;LYS A  52;LEU A  84;LEU A  96;LEU A 100","J60 A1305 (-4.8A);EDO A1304 ( 2.9A);None;None;J60 A1305 (-4.4A)","0.59A","1xkkA-2jamA:14.8","1xkkA-2jamA:25.96"],["1XKK_A_FMMA91_2","2jc6","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1D","PF00069(Pkinase)",6,"LEU A  29;VAL A  37;LYS A  52;LEU A  84;LEU A  96;LEU A 100","QPP A1314 (-3.7A);QPP A1314 ( 4.6A);None;None;None;QPP A1314 (-4.5A)","0.61A","1xkkA-2jc6A:20.4","1xkkA-2jc6A:26.21"],["1XKK_A_FMMA91_2","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 344;VAL A 352;LYS A 369;LEU A 401;LEU A 412;LEU A 482","ANP A 615 (-4.4A);ANP A 615 (-4.5A);ANP A 615 (-3.1A);None;None;None","0.91A","1xkkA-2ozoA:31.6","1xkkA-2ozoA:21.55"],["1XKK_A_FMMA91_2","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",6,"LEU A  25;VAL A  33;LEU A  89;LEU A 101;LEU A 105;MET A 106","ATP A 381 ( 4.3A);ATP A 381 (-4.1A);None;None;None;None","0.56A","1xkkA-2phkA:21.9","1xkkA-2phkA:26.32"],["1XKK_A_FMMA91_2","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",8,"LEU A 724;VAL A 732;LYS A 751;LEU A 783;LEU A 794;LEU A 798;MET A 799;LEU A 864","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.9A);GW7 A   1 (-3.9A);GW7 A   1 (-4.1A);GW7 A   1 (-4.5A);None;GW7 A   1 ( 4.7A)","0.33A","1xkkA-2r4bA:39.6","1xkkA-2r4bA:76.99"],["1XKK_A_FMMA91_2","2w4k","Homo sapiens","DEATH-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;LYS A  42;LEU A  79;LEU A  91;LEU A  95","ADP A1303 ( 3.9A);ADP A1303 (-4.0A);ADP A1303 (-2.7A);None;None;None","0.70A","1xkkA-2w4kA:17.1","1xkkA-2w4kA:24.39"],["1XKK_A_FMMA91_2","2w4o","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IV","PF00069(Pkinase)",5,"LEU A  52;VAL A  60;LEU A 104;LEU A 116;LEU A 120","DKI A1338 (-3.8A);DKI A1338 (-4.2A);None;None;DKI A1338 (-4.2A)","0.44A","1xkkA-2w4oA:22.1","1xkkA-2w4oA:27.39"],["1XKK_A_FMMA91_2","2w4o","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IV","PF00069(Pkinase)",5,"VAL A  60;LYS A  75;LEU A 104;LEU A 116;LEU A 120","DKI A1338 (-4.2A);None;None;None;DKI A1338 (-4.2A)","0.63A","1xkkA-2w4oA:22.1","1xkkA-2w4oA:27.39"],["1XKK_A_FMMA91_2","2wbi","Homo sapiens","ACYL-COA DEHYDROGENASE FAMILY MEMBER 11","PF00441(Acyl-CoA_dh_1);PF02770(Acyl-CoA_dh_M);PF02771(Acyl-CoA_dh_N)",6,"LEU A 127;VAL A 126;CYH A 153;LEU A 201;LEU A 219;LEU A 276","None","1.23A","1xkkA-2wbiA:undetectable","1xkkA-2wbiA:21.62"],["1XKK_A_FMMA91_2","2x4f","Homo sapiens","MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4","PF00069(Pkinase)",5,"LEU A 112;VAL A 120;LYS A 135;LEU A 166;LEU A 178","16X A1374 (-4.1A);16X A1374 (-4.8A);16X A1374 ( 4.3A);None;None","0.47A","1xkkA-2x4fA:22.8","1xkkA-2x4fA:25.37"],["1XKK_A_FMMA91_2","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",5,"LEU A 226;VAL A 234;LYS A 249;LEU A 303;MET A 304","XK9 A1511 (-3.8A);XK9 A1511 (-4.8A);XK9 A1511 (-4.2A);XK9 A1511 (-4.1A);None","0.73A","1xkkA-2xk9A:20.9","1xkkA-2xk9A:25.92"],["1XKK_A_FMMA91_2","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",5,"VAL A  38;LEU A  93;LEU A 105;LEU A 109;MET A 110","None;None;None;B49 A1294 ( 4.7A);None","0.45A","1xkkA-2y7jA:22.4","1xkkA-2y7jA:25.91"],["1XKK_A_FMMA91_2","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",5,"VAL A  38;LYS A  53;LEU A  93;LEU A 105;MET A 110","None","0.65A","1xkkA-2y7jA:22.4","1xkkA-2y7jA:25.91"],["1XKK_A_FMMA91_2","2yab","Mus musculus","DEATH-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",5,"LEU A  19;VAL A  27;LEU A  79;LEU A  91;LEU A  95","AMP A1302 (-3.7A);AMP A1302 (-4.2A);None;None;AMP A1302 ( 4.9A)","0.55A","1xkkA-2yabA:23.1","1xkkA-2yabA:25.44"],["1XKK_A_FMMA91_2","2yab","Mus musculus","DEATH-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",5,"VAL A  27;LYS A  42;LEU A  79;LEU A  91;LEU A  95","AMP A1302 (-4.2A);AMP A1302 (-2.8A);None;None;AMP A1302 ( 4.9A)","0.75A","1xkkA-2yabA:23.1","1xkkA-2yabA:25.44"],["1XKK_A_FMMA91_2","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",5,"LEU A  68;VAL A  76;LYS A  94;LEU A 127;LEU A 139","STU A   1 (-3.8A);None;STU A   1 (-2.8A);None;None","0.54A","1xkkA-2z7rA:22.5","1xkkA-2z7rA:26.74"],["1XKK_A_FMMA91_2","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",5,"LEU A1002;VAL A1010;LEU A1062;LEU A1078;MET A1079","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);None;S91 A   1 (-4.7A);None","0.57A","1xkkA-2z8cA:22.4","1xkkA-2z8cA:31.69"],["1XKK_A_FMMA91_2","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",5,"LEU A1002;VAL A1010;LYS A1030;LEU A1062;LEU A1078","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 ( 4.2A);None;S91 A   1 (-4.7A)","0.61A","1xkkA-2z8cA:22.4","1xkkA-2z8cA:31.69"],["1XKK_A_FMMA91_2","3a14","Thermotoga maritima","1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE","PF02670(DXP_reductoisom);PF08436(DXP_redisom_C);PF13288(DXPR_C)",5,"LEU A   9;VAL A  91;LEU A 131;LEU A 138;LEU A 120","None","0.83A","1xkkA-3a14A:undetectable","1xkkA-3a14A:22.91"],["1XKK_A_FMMA91_2","3bqr","Homo sapiens","DEATH-ASSOCIATED PROTEIN KINASE 3","PF00069(Pkinase)",5,"LEU A  19;VAL A  27;LEU A  79;LEU A  91;LEU A  95","4RB A 401 ( 3.9A);4RB A 401 ( 4.4A);PGO A 501 ( 4.6A);None;4RB A 401 (-4.4A)","0.47A","1xkkA-3bqrA:20.9","1xkkA-3bqrA:24.86"],["1XKK_A_FMMA91_2","3coi","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 13","PF00069(Pkinase)",5,"VAL A  39;LYS A  54;LEU A  87;LEU A 105;MET A 110","None","0.75A","1xkkA-3coiA:19.1","1xkkA-3coiA:26.48"],["1XKK_A_FMMA91_2","3dxn","Toxoplasma gondii","CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3","PF00069(Pkinase)",5,"LEU A  29;VAL A  37;LEU A  86;LEU A  98;LEU A 170","None","0.72A","1xkkA-3dxnA:25.2","1xkkA-3dxnA:27.95"],["1XKK_A_FMMA91_2","3e7o","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 9","PF00069(Pkinase)",6,"VAL A  40;LYS A  55;LEU A  88;LEU A 106;LEU A 110;MET A 111","35F A   1 ( 4.8A);35F A   1 ( 4.6A);None;None;35F A   1 (-4.5A);None","0.66A","1xkkA-3e7oA:19.6","1xkkA-3e7oA:25.63"],["1XKK_A_FMMA91_2","3f2a","Homo sapiens","PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE PIM-1","PF00069(Pkinase)",5,"LEU A  44;VAL A  52;LYS A  67;LEU A 106;LEU A 118","985 A   1 (-4.1A);985 A   1 (-4.5A);985 A   1 ( 2.8A);None;None","0.65A","1xkkA-3f2aA:16.9","1xkkA-3f2aA:23.95"],["1XKK_A_FMMA91_2","3f3z","Cryptosporidium parvum","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS","PF00069(Pkinase)",5,"VAL A  42;LYS A  57;LEU A  88;LEU A 100;LEU A 104","DRK A   1 ( 4.9A);DRK A   1 (-4.1A);None;None;DRK A   1 (-4.4A)","0.54A","1xkkA-3f3zA:22.2","1xkkA-3f3zA:24.79"],["1XKK_A_FMMA91_2","3gbz","Giardia intestinalis","KINASE, CMGC CDK","PF00069(Pkinase)",6,"LEU A  21;VAL A  29;LYS A  44;LEU A  77;LEU A  89;LEU A 162","None","1.10A","1xkkA-3gbzA:18.1","1xkkA-3gbzA:27.60"],["1XKK_A_FMMA91_2","3gp0","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 11","PF00069(Pkinase)",5,"VAL A  38;LEU A  86;LEU A 104;LEU A 108;MET A 109","NIL A   1 ( 4.7A);None;NIL A   1 ( 4.3A);NIL A   1 ( 4.4A);None","0.63A","1xkkA-3gp0A:20.5","1xkkA-3gp0A:25.95"],["1XKK_A_FMMA91_2","3gp0","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 11","PF00069(Pkinase)",5,"VAL A  38;LYS A  53;LEU A  86;LEU A 104;LEU A 108","NIL A   1 ( 4.7A);None;None;NIL A   1 ( 4.3A);NIL A   1 ( 4.4A)","0.67A","1xkkA-3gp0A:20.5","1xkkA-3gp0A:25.95"],["1XKK_A_FMMA91_2","3hko","Cryptosporidium parvum","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS","PF00069(Pkinase)",5,"VAL A  24;LYS A  39;LEU A  75;LEU A  87;LEU A  91","ANP A 329 (-4.4A);ANP A 329 (-2.7A);None;None;ANP A 329 ( 4.7A)","0.79A","1xkkA-3hkoA:20.1","1xkkA-3hkoA:25.74"],["1XKK_A_FMMA91_2","3igo","Cryptosporidium parvum","CALMODULIN-DOMAIN PROTEIN KINASE 1","PF00069(Pkinase);PF13499(EF-hand_7)",5,"LEU A  82;VAL A  90;LYS A 105;LEU A 154;LEU A 222","ANP A 610 ( 4.5A);ANP A 610 (-3.9A);ANP A 610 (-2.8A);GOL A   1 (-4.6A);None","0.80A","1xkkA-3igoA:21.9","1xkkA-3igoA:24.42"],["1XKK_A_FMMA91_2","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",5,"LEU A 696;VAL A 704;LYS A 723;LEU A 755;LEU A 766","ANP A   1 (-4.4A);ANP A   1 (-3.9A);ANP A   1 (-3.4A);None;None","0.40A","1xkkA-3kexA:36.0","1xkkA-3kexA:51.14"],["1XKK_A_FMMA91_2","3kl8","Caenorhabditis elegans","CALCIUM\/CALMODULIN DEPENDENT PROTEIN KINASE II","PF00069(Pkinase)",5,"VAL A  27;LYS A  42;LEU A  75;LEU A  87;LEU A  91","None","0.56A","1xkkA-3kl8A:21.4","1xkkA-3kl8A:23.78"],["1XKK_A_FMMA91_2","3lij","Cryptosporidium parvum","CALCIUM\/CALMODULIN DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS","PF00069(Pkinase);PF13499(EF-hand_7)",5,"LEU A  68;VAL A  76;LYS A  91;LEU A 124;LEU A 136","ANP A 522 (-4.6A);ANP A 522 (-4.1A);ANP A 522 (-3.5A);None;None","0.53A","1xkkA-3lijA:23.2","1xkkA-3lijA:23.66"],["1XKK_A_FMMA91_2","3lm5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 17B","PF00069(Pkinase)",5,"LEU A  39;VAL A  47;LYS A  62;LEU A  96;LEU A 108","QUE A   1 ( 3.8A);QUE A   1 ( 4.6A);QUE A   1 (-4.1A);None;None","0.78A","1xkkA-3lm5A:23.3","1xkkA-3lm5A:27.59"],["1XKK_A_FMMA91_2","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 694;VAL A 702;CYH A 751;LEU A 753;LEU A 768;MET A 769","ITI A   1 (-3.9A);ITI A   1 (-4.8A);ITI A   1 (-3.7A);ITI A   1 (-3.8A);ITI A   1 (-4.8A);ITI A   1 (-4.8A)","1.14A","1xkkA-3lzbA:38.3","1xkkA-3lzbA:87.77"],["1XKK_A_FMMA91_2","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 694;VAL A 702;LEU A 753;LEU A 764;LEU A 768;MET A 769","ITI A   1 (-3.9A);ITI A   1 (-4.8A);ITI A   1 (-3.8A);ITI A   1 ( 4.2A);ITI A   1 (-4.8A);ITI A   1 (-4.8A)","0.93A","1xkkA-3lzbA:38.3","1xkkA-3lzbA:87.77"],["1XKK_A_FMMA91_2","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 694;VAL A 702;LYS A 721;LEU A 753;LEU A 764;LEU A 768","ITI A   1 (-3.9A);ITI A   1 (-4.8A);ITI A   1 (-2.6A);ITI A   1 (-3.8A);ITI A   1 ( 4.2A);ITI A   1 (-4.8A)","0.81A","1xkkA-3lzbA:38.3","1xkkA-3lzbA:87.77"],["1XKK_A_FMMA91_2","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 702;CYH A 751;LEU A 753;LEU A 768;MET A 769;LEU A 834","ITI A   1 (-4.8A);ITI A   1 (-3.7A);ITI A   1 (-3.8A);ITI A   1 (-4.8A);ITI A   1 (-4.8A);None","1.19A","1xkkA-3lzbA:38.3","1xkkA-3lzbA:87.77"],["1XKK_A_FMMA91_2","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 702;LEU A 753;LEU A 764;LEU A 768;MET A 769;LEU A 834","ITI A   1 (-4.8A);ITI A   1 (-3.8A);ITI A   1 ( 4.2A);ITI A   1 (-4.8A);ITI A   1 (-4.8A);None","1.01A","1xkkA-3lzbA:38.3","1xkkA-3lzbA:87.77"],["1XKK_A_FMMA91_2","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 702;LYS A 721;LEU A 753;LEU A 764;LEU A 768;LEU A 834","ITI A   1 (-4.8A);ITI A   1 (-2.6A);ITI A   1 (-3.8A);ITI A   1 ( 4.2A);ITI A   1 (-4.8A);None","0.95A","1xkkA-3lzbA:38.3","1xkkA-3lzbA:87.77"],["1XKK_A_FMMA91_2","3niz","Cryptosporidium parvum","RHODANESE FAMILY PROTEIN","PF00069(Pkinase)",5,"VAL A  37;LYS A  51;LEU A  84;LEU A  96;MET A 101","ADP A 314 (-4.0A);ADP A 314 (-2.8A);None;None;None","0.78A","1xkkA-3nizA:22.6","1xkkA-3nizA:29.06"],["1XKK_A_FMMA91_2","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 192;VAL A 200;LEU A 238;LEU A 261;LEU A 265;MET A 266","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);None;None;AMP A 577 ( 4.9A);None","1.17A","1xkkA-3nyoA:21.4","1xkkA-3nyoA:19.35"],["1XKK_A_FMMA91_2","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 192;VAL A 200;LEU A 249;LEU A 261;LEU A 265;MET A 266","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);None;None;AMP A 577 ( 4.9A);None","0.70A","1xkkA-3nyoA:21.4","1xkkA-3nyoA:19.35"],["1XKK_A_FMMA91_2","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",6,"VAL A 200;LYS A 215;LEU A 249;LEU A 261;LEU A 265;MET A 266","AMP A 577 (-4.3A);AMP A 577 (-2.8A);None;None;AMP A 577 ( 4.9A);None","0.77A","1xkkA-3nyoA:21.4","1xkkA-3nyoA:19.35"],["1XKK_A_FMMA91_2","3oht","Salmo salar","P38A","PF00069(Pkinase)",5,"LYS A  54;LEU A  87;LEU A 105;LEU A 109;MET A 110","1N1 A1000 (-4.5A);None;1N1 A1000 (-4.2A);1N1 A1000 (-4.7A);None","0.77A","1xkkA-3ohtA:6.8","1xkkA-3ohtA:27.85"],["1XKK_A_FMMA91_2","3oht","Salmo salar","P38A","PF00069(Pkinase)",5,"VAL A  39;LEU A  87;LEU A 105;LEU A 109;MET A 110","1N1 A1000 (-4.6A);None;1N1 A1000 (-4.2A);1N1 A1000 (-4.7A);None","0.77A","1xkkA-3ohtA:6.8","1xkkA-3ohtA:27.85"],["1XKK_A_FMMA91_2","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"LEU A 726;VAL A 734;LEU A 785;LEU A 796;LEU A 800;MET A 801","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.3A);03Q A   1 (-4.6A);None","0.31A","1xkkA-3pp0A:29.5","1xkkA-3pp0A:73.86"],["1XKK_A_FMMA91_2","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"VAL A 734;LYS A 753;LEU A 785;LEU A 796;LEU A 800;MET A 801","03Q A   1 (-4.5A);03Q A   1 (-4.7A);03Q A   1 (-3.1A);03Q A   1 (-4.3A);03Q A   1 (-4.6A);None","0.55A","1xkkA-3pp0A:29.5","1xkkA-3pp0A:73.86"],["1XKK_A_FMMA91_2","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",5,"LEU A  63;VAL A  71;LYS A  86;LEU A 130;LEU A 142","ANP A1634 ( 4.3A);ANP A1634 (-4.1A);ANP A1634 (-3.1A);None;None","0.68A","1xkkA-3q5iA:21.2","1xkkA-3q5iA:23.85"],["1XKK_A_FMMA91_2","3soa","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II SUBUNIT ALPHA WITH A BETA 7 LINKER","PF00069(Pkinase);PF08332(CaMKII_AD)",5,"LEU A  19;VAL A  27;LEU A  75;LEU A  87;LEU A  91","DB8 A 445 (-3.5A);DB8 A 445 (-4.5A);None;None;None","0.73A","1xkkA-3soaA:19.3","1xkkA-3soaA:23.65"],["1XKK_A_FMMA91_2","3sxf","Toxoplasma gondii","CALMODULIN-DOMAIN PROTEIN KINASE 1","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  57;VAL A  65;LYS A  80;LEU A 114;LEU A 126;LEU A 198","BK5 A 701 ( 4.2A);BK5 A 701 (-4.2A);BK5 A 701 (-3.5A);BK5 A 701 ( 4.5A);BK5 A 701 (-3.3A);BK5 A 701 ( 4.9A)","0.52A","1xkkA-3sxfA:24.2","1xkkA-3sxfA:22.33"],["1XKK_A_FMMA91_2","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",5,"LEU A 295;LYS A 317;LEU A 349;LEU A 361;MET A 366","None","0.69A","1xkkA-3ulzA:22.3","1xkkA-3ulzA:26.44"],["1XKK_A_FMMA91_2","3w18","Homo sapiens","AURORA KINASE A","PF00069(Pkinase)",5,"LEU A 139;VAL A 147;LYS A 162;LEU A 196;LEU A 208","N13 A 501 (-3.7A);N13 A 501 ( 4.7A);N13 A 501 (-2.9A);N13 A 501 ( 4.8A);N13 A 501 (-4.9A)","0.52A","1xkkA-3w18A:21.6","1xkkA-3w18A:23.20"],["1XKK_A_FMMA91_2","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",5,"LEU A  83;VAL A  91;LYS A 106;LEU A 140;LEU A 152","VX6 A 500 (-3.8A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.3A);None;None","0.53A","1xkkA-4af3A:19.0","1xkkA-4af3A:24.58"],["1XKK_A_FMMA91_2","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"LEU A 616;VAL A 624;LYS A 655;LEU A 687;MET A 704","None;DI1 A1000 (-4.8A);DI1 A1000 (-3.9A);None;None","0.81A","1xkkA-4ckrA:27.4","1xkkA-4ckrA:31.91"],["1XKK_A_FMMA91_2","4eut","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",5,"LEU A  15;VAL A  23;LYS A  38;LEU A  70;LEU A  84","BX7 A 401 (-3.7A);BX7 A 401 (-4.4A);BX7 A 401 ( 4.0A);None;None","0.73A","1xkkA-4eutA:11.1","1xkkA-4eutA:23.71"],["1XKK_A_FMMA91_2","4fg8","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1","PF00069(Pkinase)",6,"LEU A  26;VAL A  34;LYS A  49;LEU A  81;LEU A  93;LEU A  97","ATP A 401 (-3.8A);ATP A 401 (-4.1A);ATP A 401 (-3.0A);None;None;ATP A 401 ( 4.8A)","0.62A","1xkkA-4fg8A:22.8","1xkkA-4fg8A:25.00"],["1XKK_A_FMMA91_2","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",5,"LEU A 377;VAL A 385;LYS A 402;LEU A 446;LEU A 515","ANP A 701 ( 4.6A);ANP A 701 (-4.1A);ANP A 701 (-2.7A);None;None","0.44A","1xkkA-4fl3A:21.9","1xkkA-4fl3A:22.75"],["1XKK_A_FMMA91_2","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"LEU A 132;VAL A 140;LYS A 158;LEU A 192;LEU A 207;LEU A 273","None","0.70A","1xkkA-4hzsA:21.6","1xkkA-4hzsA:36.39"],["1XKK_A_FMMA91_2","4i93","Arabidopsis thaliana","PROBABLE SERINE\/THREONINE-PROTEIN KINASE AT5G41260","PF07714(Pkinase_Tyr)",5,"VAL A  73;LYS A  87;LEU A 118;LEU A 130;MET A 135","None","0.72A","1xkkA-4i93A:23.9","1xkkA-4i93A:25.41"],["1XKK_A_FMMA91_2","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",5,"LEU A 132;VAL A 140;LYS A 158;LEU A 192;LEU A 207","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.7A);1G0 A 401 ( 3.8A);1G0 A 401 ( 4.9A)","0.72A","1xkkA-4id7A:30.5","1xkkA-4id7A:34.37"],["1XKK_A_FMMA91_2","4jxf","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK4","PF00069(Pkinase)",5,"LEU A  18;VAL A  26;LYS A  41;LEU A  75;LEU A  87","631 A 301 (-3.4A);631 A 301 (-4.6A);631 A 301 (-2.7A);None;None","0.67A","1xkkA-4jxfA:18.4","1xkkA-4jxfA:25.22"],["1XKK_A_FMMA91_2","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;LYS A 295;LEU A 325;MET A 341;LEU A 407","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 ( 4.7A);None;None;None","0.76A","1xkkA-4k11A:33.1","1xkkA-4k11A:26.06"],["1XKK_A_FMMA91_2","4l68","Arabidopsis thaliana","LEUCINE-RICH REPEAT PROTEIN KINASE-LIKE PROTEIN","PF07714(Pkinase_Tyr)",5,"LYS A 335;LEU A 365;LEU A 377;MET A 382;LEU A 450","None","0.54A","1xkkA-4l68A:22.3","1xkkA-4l68A:23.98"],["1XKK_A_FMMA91_2","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"VAL A  36;LYS A  51;LEU A  76;LEU A  93;MET A  98;LEU A 164","ANP A 401 (-4.5A);ANP A 401 (-2.9A);None;None;None;None","0.67A","1xkkA-4m69A:27.3","1xkkA-4m69A:25.26"],["1XKK_A_FMMA91_2","4mvf","Plasmodium falciparum","CALCIUM-DEPENDENT PROTEIN KINASE 2","PF00069(Pkinase);PF13499(EF-hand_7)",5,"LEU A  78;VAL A  86;LEU A 132;LEU A 144;LEU A 148","STU A 601 ( 4.0A);STU A 601 (-4.8A);None;None;STU A 601 (-4.3A)","0.50A","1xkkA-4mvfA:19.0","1xkkA-4mvfA:24.60"],["1XKK_A_FMMA91_2","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",5,"LEU A  46;VAL A  54;LYS A  69;LEU A 121;LEU A 125","SIN A 401 ( 3.9A);None;None;None;SIN A 401 ( 4.8A)","0.59A","1xkkA-4o38A:18.7","1xkkA-4o38A:21.50"],["1XKK_A_FMMA91_2","4rgj","Plasmodium falciparum","CALCIUM-DEPENDENT PROTEIN KINASE 4","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  76;VAL A  84;LYS A  99;LEU A 133;LEU A 145;LEU A 218","None","0.65A","1xkkA-4rgjA:23.4","1xkkA-4rgjA:22.55"],["1XKK_A_FMMA91_2","4tyh","Mus musculus","MITOGEN-ACTIVATED PROTEIN KINASE 14","PF00069(Pkinase)",6,"VAL B  38;LYS B  53;LEU B  86;LEU B 104;LEU B 108;MET B 109","None;39G B 401 (-4.2A);None;39G B 401 ( 4.7A);39G B 401 ( 4.9A);39G B 401 (-4.8A)","0.68A","1xkkA-4tyhB:20.6","1xkkA-4tyhB:25.65"],["1XKK_A_FMMA91_2","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 193;VAL A 201;LYS A 216;LEU A 250;LEU A 262;MET A 267","ANW A 601 ( 4.0A);None;None;None;None;None","0.65A","1xkkA-4wboA:21.7","1xkkA-4wboA:21.68"],["1XKK_A_FMMA91_2","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",5,"LEU A 193;VAL A 201;LEU A 250;LEU A 262;MET A 267","AN2 A 601 ( 4.2A);AN2 A 601 (-4.0A);None;None;None","0.82A","1xkkA-4yhjA:20.2","1xkkA-4yhjA:22.28"],["1XKK_A_FMMA91_2","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",5,"VAL A 201;LYS A 216;LEU A 250;LEU A 262;MET A 267","AN2 A 601 (-4.0A);AN2 A 601 ( 3.9A);None;None;None","0.81A","1xkkA-4yhjA:20.2","1xkkA-4yhjA:22.28"],["1XKK_A_FMMA91_2","4ynz","Mus musculus","SERINE\/THREONINE-PROTEIN KINASE BRSK2","PF00069(Pkinase)",5,"LEU A  26;VAL A  34;LYS A  49;LEU A  82;LEU A  94","None","0.42A","1xkkA-4ynzA:21.7","1xkkA-4ynzA:24.55"],["1XKK_A_FMMA91_2","4ysj","Eimeria tenella","CALMODULIN-LIKE DOMAIN PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",5,"LEU A  34;VAL A  42;LYS A  57;LEU A  91;LEU A 103","ADP A 506 ( 3.8A);ADP A 506 (-4.3A);ADP A 506 (-2.4A);None;None","0.64A","1xkkA-4ysjA:23.5","1xkkA-4ysjA:22.49"],["1XKK_A_FMMA91_2","5awm","Drosophila melanogaster","STRESS-ACTIVATED PROTEIN KINASE JNK","PF00069(Pkinase)",6,"VAL A  38;LYS A  53;LEU A  86;LEU A 104;LEU A 108;MET A 109","ANP A 401 (-4.5A);ANP A 401 (-2.9A);None;None;ANP A 401 ( 4.8A);None","0.48A","1xkkA-5awmA:19.4","1xkkA-5awmA:25.72"],["1XKK_A_FMMA91_2","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",5,"LEU A  20;VAL A  28;LEU A  76;LEU A  88;LEU A  92","ADP A 301 ( 4.0A);ADP A 301 (-3.7A);None;None;ADP A 301 ( 4.8A)","0.46A","1xkkA-5hu3A:16.7","1xkkA-5hu3A:24.32"],["1XKK_A_FMMA91_2","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",5,"VAL A  28;LYS A  43;LEU A  76;LEU A  88;LEU A  92","ADP A 301 (-3.7A);ADP A 301 (-2.7A);None;None;ADP A 301 ( 4.8A)","0.75A","1xkkA-5hu3A:16.7","1xkkA-5hu3A:24.32"],["1XKK_A_FMMA91_2","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 718;VAL A 726;CYH A 775;LEU A 777;LEU A 788;LEU A 792;MET A 793","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);None;None;6HJ A1101 ( 4.6A);6HJ A1101 ( 4.9A);None","0.60A","1xkkA-5j9zA:32.5","1xkkA-5j9zA:99.69"],["1XKK_A_FMMA91_2","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 726;LYS A 745;CYH A 775;LEU A 777;LEU A 788;LEU A 792;MET A 793","6HJ A1101 ( 4.7A);6HJ A1101 (-4.2A);None;None;6HJ A1101 ( 4.6A);6HJ A1101 ( 4.9A);None","0.68A","1xkkA-5j9zA:32.5","1xkkA-5j9zA:99.69"],["1XKK_A_FMMA91_2","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",5,"VAL A 897;LYS A 911;LEU A 942;LEU A 954;MET A 959","ATP A1200 ( 4.5A);ATP A1200 (-3.8A);None;None;None","0.77A","1xkkA-5lpyA:23.0","1xkkA-5lpyA:26.68"],["1XKK_A_FMMA91_2","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",5,"VAL A 897;LYS A 911;LEU A 942;LEU A 954;MET A 959","ADP A1200 (-4.4A);ADP A1200 ( 4.3A);None;None;None","0.80A","1xkkA-5lpzA:22.9","1xkkA-5lpzA:25.66"],["1XKK_A_FMMA91_2","5o2c","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE WNK3","PF00069(Pkinase);PF12202(OSR1_C)",5,"LEU A 153;VAL A 161;LEU A 225;LEU A 229;MET A 230","None;None;None;GOL A 604 ( 4.8A);None","0.83A","1xkkA-5o2cA:25.8","1xkkA-5o2cA:26.13"],["1XKK_A_FMMA91_2","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",5,"LEU A 116;VAL A 124;LEU A 173;LEU A 185;LEU A 189","H8H A 401 (-3.7A);H8H A 401 (-4.7A);None;H8H A 401 (-4.3A);None","0.76A","1xkkA-5vcxA:22.7","1xkkA-5vcxA:25.00"],["1XKK_A_FMMA91_2","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",5,"VAL A 142;LYS A 157;LEU A 214;LEU A 228;LEU A 232","H1N A 501 (-4.4A);H1N A 501 (-2.8A);None;None;H1N A 501 (-4.3A)","0.63A","1xkkA-6ccfA:22.8","1xkkA-6ccfA:14.90"],["1XKK_A_FMMA91_2","6cth","Theobroma cacao","CONCANAVALIN A-LIKE LECTIN PROTEIN KINASE FAMILY PROTEIN","no annotation",5,"LEU A 275;VAL A 283;LEU A 329;LEU A 341;MET A 346","FE7 A 601 (-3.8A);FE7 A 601 ( 4.3A);None;None;FE7 A 601 (-4.7A)","0.74A","1xkkA-6cthA:21.7","1xkkA-6cthA:11.68"],["1XKK_A_FMMA91_2","6cth","Theobroma cacao","CONCANAVALIN A-LIKE LECTIN PROTEIN KINASE FAMILY PROTEIN","no annotation",5,"VAL A 283;LYS A 298;LEU A 329;LEU A 341;MET A 346","FE7 A 601 ( 4.3A);FE7 A 601 (-3.6A);None;None;FE7 A 601 (-4.7A)","0.74A","1xkkA-6cthA:21.7","1xkkA-6cthA:11.68"],["1XKK_A_FMMA91_2","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",7,"LEU A 197;VAL A 205;LYS A 219;LEU A 250;LEU A 266;MET A 267;LEU A 333","FKY A9001 (-4.1A);FKY A9001 ( 4.6A);None;None;FKY A9001 (-4.4A);None;None","0.83A","1xkkA-6cz4A:30.2","1xkkA-6cz4A:16.67"]]